{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:02:11Z","timestamp":1789603331881,"version":"build-2803163510"},"reference-count":62,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das metastasierte kastrationsresistente Prostatakarzinom (mCRPC) ist eine biologisch\n      heterogene Tumorerkrankung. Alterationen in Genen der homologen Rekombinationsreperatur (HRR)\n      oder Defekte im Mismatch-Reparatursystem (MMR) sowie klassische Tumorsuppressorgene wie TP53,\n      RB1 und PTEN aber auch Androgenrezeptor-Resistenzen, beg\u00fcnstigen aggressive Krankheitsverl\u00e4ufe\n      und k\u00f6nnen das Therapieansprechen beeinflussen. Molekulardiagnostische Verfahren gewinnen an\n      Relevanz und erm\u00f6glichen eine zunehmend individualisierte Charakterisierung des Tumors. Auf\n      dieser Grundlage stehen zunehmend zielgerichtete Therapieoptionen zur Verf\u00fcgung bzw. werden\n      erforscht. Innovative Therapiekonzepte wie T-Zell-Engager, CAR (chimeric antigen\n      receptor)-T-Zell-Therapie und Androgenrezeptor (AR)-Degrader befinden sich in pr\u00e4klinischen\n      oder fr\u00fch-klinischer Forschung. Diese \u00dcbersicht fasst den aktuellen Stand der molekularen\n      Diagnostik und der personalisierten Therapie des mCRPC zusammen und diskutiert, weshalb eine\n      patientenindividuelle, tumorspezifische Therapie im mCRPC zunehmend an Bedeutung\n      gewinnt.<\/jats:p>","DOI":"10.1055\/a-2927-6325","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:10:43Z","timestamp":1789600243000},"source":"Crossref","is-referenced-by-count":0,"title":["Molekulardiagnostik und personalisierte Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC)"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5634-3627","authenticated-orcid":false,"given":"Marie","family":"Semmler","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Germany","place":["M\u00fcnchen"],"department":["Urologische Klinik und Poliklinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Germany","place":["M\u00fcnchen"],"department":["Urologische Klinik und Poliklinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsKlinikum Heidelberg, BW, Germany","place":["Heidelberg"],"department":["NCT Heidelberg, Abt. Medizinische Onkologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann-Christoph","family":"Jann","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsKlinikum Heidelberg, BW, Germany","place":["Heidelberg"],"department":["NCT Heidelberg, Abt. Medizinische Onkologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041.","article-title":"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic\n          Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III\n          ARASENS Trial","volume":"41","author":"M Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1.","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in\n          de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre,\n          open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"K Fizazi","year":"2022","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8.","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic\n          castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"G Attard","year":"2025","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41391-024-00906-z.","article-title":"Navigating therapeutic sequencing in the metastatic castration-resistant prostate\n          cancer patient journey","volume":"28","author":"HD McManus","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00120-024-02493-2.","article-title":"NGS-basierte (\u201enext generation sequencing\u201c) molekulare Panelanalyse des\n          metastasierten Prostatakarzinoms: Wie h\u00e4ufig finden wir therapierbare\n          Mutationen?","volume":"64","author":"O Steenbock","year":"2025","journal-title":"Urologie"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5.","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate\n          cancer: a randomised, phase 3 trial","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344.","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"CJ Lord","year":"2017","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720.","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate\n          cancer","volume":"351","author":"IF Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100146.","article-title":"Liquid biopsy into the clinics: Current evidence and future\n          perspectives","volume":"4","author":"M Boukovala","year":"2024","journal-title":"J Liq Biopsy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.12.024.","article-title":"Routine application of next-generation sequencing testing in uro-oncology\u2014Are we\n          ready for the next step of personalised medicine?","volume":"146","author":"S Rodler","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144.","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate\n          Cancer","volume":"375","author":"CC Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001.","article-title":"Integrative Clinical Genomics of Advanced Prostate Cancer","volume":"161","author":"D Robinson","year":"2015","journal-title":"Cell"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760.","article-title":"Prevalence of Germline Variants in Prostate Cancer and Implications for Current\n          Genetic Testing Guidelines","volume":"5","author":"P Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440.","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"J de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1200\/JCO.2023.41.16_suppl.5003","article-title":"Presence of somatic\/germline homologous recombination repair (HRR) mutations and\n          outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)\n          receiving first-line (1L) treatment stratified by BRCA status","volume":"41","author":"D Olmos","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/po.19.00346.","article-title":"Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene\n          Alterations","volume":"4","author":"JM Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.euo.2023.09.001.","article-title":"Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum\n          Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate\n          Cancer. A Systematic Review and Meta-analysis","volume":"7","author":"T Fazekas","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596.","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"DT Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801.","article-title":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and\n          Response to Immune Checkpoint Blockade","volume":"5","author":"W Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001.","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune\n          checkpoint inhibitors","volume":"62","author":"KM Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9060067.","article-title":"Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate\n          Cancer Therapy Resistance","volume":"9","author":"DJ Crona","year":"2017","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155.","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on\n          enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution\n          correlative biomarker study","volume":"28","author":"V Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815.","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"ES Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z.","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"J Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00432-024-05983-0.","article-title":"Unraveling molecular characteristics and tumor microenvironment dynamics of\n          neuroendocrine prostate cancer","volume":"150","author":"D Heimd\u00f6rfer","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9.","article-title":"Clinical and Biological Features of Neuroendocrine Prostate Cancer","volume":"23","author":"Y Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-022-02255-y.","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine\n          transdifferentiation","volume":"41","author":"L Merkens","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025237.","article-title":"Clinicopathological characteristics and survival outcomes in neuroendocrine\n          prostate cancer: A population-based study","volume":"100","author":"J Zhu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1055\/a-2651-1738.","article-title":"Molecular Tumour Boards for Urological Tumours: Hope or Disappointment?","volume":"57","author":"NT Gaisa","year":"2026","journal-title":"Aktuelle Urol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322.","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate\n          Cancer","volume":"385","author":"O Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2967\/jnumed.121.262017.","article-title":"Effects of (225)Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy\n          in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis","volume":"63","author":"DY Lee","year":"2022","journal-title":"J Nucl Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/17562872231182219.","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate\n          cancer","volume":"15","author":"KK Zarrabi","year":"2023","journal-title":"Ther Adv Urol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3.","article-title":"(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic\n          castration-resistant prostate cancer (TheraP","volume":"397","author":"MS Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030.","article-title":"Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in\n          Prostate Cancer","volume":"76","author":"A Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2967\/jnumed.123.267234.","article-title":"RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA\n          Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate\n          Cancer","volume":"65","author":"A Gafita","year":"2024","journal-title":"J Nucl Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1.","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate\n          cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric\n          analysis","volume":"48","author":"R Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00259-023-06476-x.","article-title":"Change in total lesion PSMA (TLP) during [(177)Lu]Lu-PSMA-617 radioligand therapy\n          predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective\n          registry","volume":"51","author":"C Burgard","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.23.02182.","article-title":"US Food and Drug Administration Approval Summary: Talazoparib in Combination With\n          Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated\n          Metastatic Castration-Resistant Prostate Cancer","volume":"42","author":"BL Heiss","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.23.01868.","article-title":"FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of\n          Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","volume":"42","author":"J Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105.","article-title":"Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in\n          Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate\n          Cancer: A US Food and Drug Administration Pooled Analysis","volume":"42","author":"J Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0.","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic\n          castration-resistant prostate cancer (PROpel): final prespecified overall survival results\n          of a randomised, double-blind, phase 3 trial","volume":"24","author":"F Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009.","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic\n          castration-resistant prostate cancer and homologous recombination repair gene alterations:\n          second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"KN Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3.","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic\n          castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase\n          3 trial","volume":"402","author":"N Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X.","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic\n          castration-resistant prostate cancer: final overall survival results from the randomised,\n          placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"K Fizazi","year":"2025","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1200\/JCO.2025.43.16_suppl.5019","article-title":"Exploratory analyses of homologous recombination repair alterations (HRRm) by gene\n          subgroup and potential associations with efficacy in the HRR-deficient population from\n          TALAPRO-2","volume":"43","author":"S Zschaebitz","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/0008-5472.CAN-07-3095.","article-title":"Epitope landscape in breast and colorectal cancer","volume":"68","author":"NH Segal","year":"2008","journal-title":"Cancer Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733.","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1\n          blockade","volume":"357","author":"DT Le","year":"2017","journal-title":"Science"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1002\/pros.24343.","article-title":"Mismatch repair deficiency and clinical implications in prostate cancer","volume":"82","author":"LS Graham","year":"2022","journal-title":"Prostate"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206.","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate\n          Cancer","volume":"381","author":"R de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005.","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with\n          advanced cancer in 2024: a report from the ESMO Precision Medicine Working\n          Group","volume":"35","author":"MF Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant\n          prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3\n          trial","volume":"398","author":"C Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"01","key":"ref55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004.","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive\n          prostate cancer: CAPItello-281 phase III study","volume":"37","author":"K Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.01.","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in\n          metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"X Gao","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011.","article-title":"ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader,\n          in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1\/2\n          study","volume":"42","author":"DP Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.","article-title":"A clinically relevant androgen receptor mutation confers resistance to\n          second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"JD Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978.","article-title":"A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific\n          T-cell Engager for Metastatic Castration-Resistant Prostate Cancer","volume":"30","author":"T Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.2026.44.7_suppl.17","article-title":"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked\n          PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer\n          (mCRPC)","volume":"44","author":"JS De Bono","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3389\/fimmu.2026.1819701","article-title":"PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate\n          cancer: a next-generation engineering perspective on stem cell-derived immune\n          effectors","volume":"17","author":"M Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a\n          phase 1 trial","volume":"30","author":"TB Dorff","year":"2024","journal-title":"Nat Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41551-025-01508-3.","article-title":"Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat\n          prostate cancer in mouse models","volume":"10","author":"K Sasaki","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3389\/fonc.2026.1659869","article-title":"Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment\n          and enhancing efficacy","volume":"16","author":"Z Zhou","year":"2026","journal-title":"Frontiers in Oncology"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2927-6325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:10:45Z","timestamp":1789600245000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2927-6325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1055\/a-2927-6325","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}